Literature DB >> 27091293

Ketoroloac tromethamine loaded nanodispersion incorporated into thermosensitive in situ gel for prolonged ocular delivery.

Nadia Morsi1, Dalia Ghorab1, Hanan Refai2, Hoda Teba3.   

Abstract

The present study was designed to improve the ocular availability of ketorolac tromethamine and to prolong its precorneal residence time for the treatment of postoperative ocular inflammation. Ketorolac tromethamine nanodispersions were successfully prepared by nanoprecipitation method using Eudragit(®) RL100. These nanodispersions were characterized in terms of particle size, zeta potential, entrapment efficiency and in vitro release. Consequently, the optimum nanodispersion was incorporated into thermosensitive in situ gel. The optimum gelling capacity was obtained by 20% Pluronic(®) F-127 and 14% Pluronic(®) F-127/1.5% HPMC K4m. The gelling temperature and gelation time of the in situ gels increased by decreasing the concentration of Pluronic(®) F-127. The mucoadhesive strength was significantly improved by the addition of HPMC. Incorporation of ketorolac tromethamine loaded nanodispersions into in situ gel bases sustained the release of ketorolac tromethamine, improved its ocular availability and prolonged its residence time without causing irritation to eye.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Eudragit RL100 nanoparticles; In situ gel; Nanoprecipitation method; Ocular availability; Ocular retention; Pluronics

Mesh:

Substances:

Year:  2016        PMID: 27091293     DOI: 10.1016/j.ijpharm.2016.04.021

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  20 in total

Review 1.  Advances and limitations of drug delivery systems formulated as eye drops.

Authors:  Clotilde Jumelle; Shima Gholizadeh; Nasim Annabi; Reza Dana
Journal:  J Control Release       Date:  2020-02-03       Impact factor: 9.776

Review 2.  Bioresponsive Injectable Hydrogels for On-demand Drug Release and Tissue Engineering.

Authors:  Arti Vashist; Ajeet Kaushik; Kayla Alexis; Rahul Dev Jayant; Vidya Sagar; Atul Vashist; Madhavan Nair
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

3.  In situ nanostructured hydrogel of resveratrol for brain targeting: in vitro-in vivo characterization.

Authors:  Amarjitsing Rajput; Aditi Bariya; Ahmed Allam; Sarah Othman; Shital B Butani
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 4.  Novel Eye Drop Delivery Systems: Advance on Formulation Design Strategies Targeting Anterior and Posterior Segments of the Eye.

Authors:  Yaru Wang; Changhong Wang
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

5.  Exploring a Novel Fasudil-Phospholipid Complex Formulated as Liposomal Thermosensitive in situ Gel for Glaucoma.

Authors:  Aya M Khallaf; Riham M El-Moslemany; Mahmoud F Ahmed; Mahmoud H Morsi; Nawal M Khalafallah
Journal:  Int J Nanomedicine       Date:  2022-01-11

6.  Ocular Application of Dirithromycin Incorporated Polymeric Nanoparticles: an In Vitro Evaluation.

Authors:  Ebru Başaran
Journal:  Turk J Pharm Sci       Date:  2017-08-15

7.  Ocular administration of acetazolamide microsponges in situ gel formulations.

Authors:  Manar M Obiedallah; A M Abdel-Mageed; Tahani H Elfaham
Journal:  Saudi Pharm J       Date:  2018-09-24       Impact factor: 4.330

8.  Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.

Authors:  Rofida Albash; Mohamed A El-Nabarawi; Hanan Refai; Aly A Abdelbary
Journal:  Int J Nanomedicine       Date:  2019-08-15

Review 9.  Research progress of in-situ gelling ophthalmic drug delivery system.

Authors:  Yumei Wu; Yuanyuan Liu; Xinyue Li; Dereje Kebebe; Bing Zhang; Jing Ren; Jun Lu; Jiawei Li; Shouying Du; Zhidong Liu
Journal:  Asian J Pharm Sci       Date:  2018-05-24       Impact factor: 6.598

Review 10.  Research progress in the application of in situ hydrogel system in tumor treatment.

Authors:  Weipeng Wei; Hongfang Li; Chengchen Yin; Fushan Tang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.